Skip to main content
SpringerLink
Log in

Cytotoxic chemotherapy for metastatic renal cell carcinoma

  • Main topic
  • Published:
Der Urologe Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Motzer RJ, Russo P (2000) Systemic therapy for renal cell carcinoma. J Urol 163:408–417

    Article  CAS  PubMed  Google Scholar 

  2. Kish JA, Wolf M, Crawford ED, et al (1994) Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group Study. Cancer 74:916–919

    Article  CAS  PubMed  Google Scholar 

  3. Mertens WC, Eisenhauer EA, Moore M, et al (1993) Gemcitabine in advanced renal cell carcinoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 4:331–332

    CAS  PubMed  Google Scholar 

  4. Weissbach L, de Mulder P, Osieka R, et al (1992) Phase II study of gemcitabine in renal cancer. Proc Am Soc Clin Oncol 11:219

    Google Scholar 

  5. Townsley CA, Chi K, Ernst DS, et al (2003) Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 21:1524–1529

    Article  CAS  PubMed  Google Scholar 

  6. Rini BI, Vogelzang NJ, Dumas MC, Wade JL, 3rd, Taber DA, Stadler WM (2000) Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol 18:2419–2426

    CAS  PubMed  Google Scholar 

  7. Ryan CW, Vogelzang NJ, Stadler WM (2002) A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma. Cancer 94:2602–2609

    Article  CAS  PubMed  Google Scholar 

  8. Desai AA, Vogelzang NJ, Rini BI, Ansari R, Krauss S, Stadler WM (2002) A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer 95:1629–1636

    Article  CAS  PubMed  Google Scholar 

  9. George CM, Vogelzang NJ, Rini BI, Geoffroy FJ, Kollipara P, Stadler WM (2002) A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma. Ann Oncol 13:116–120

    Article  CAS  PubMed  Google Scholar 

  10. Stadler WM, Huo D, George C, et al (2003) Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. J Urol 170:1141–1145

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest:

No information supplied.

Author information

Authors and Affiliations

  1. The University of Chicago, Chicago

    Walter M. Stadler

Authors
  1. Walter M. Stadler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Walter M. Stadler.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stadler, W.M. Cytotoxic chemotherapy for metastatic renal cell carcinoma. Urologe 43 (Suppl 3), 145–146 (2004). https://doi.org/10.1007/s00120-004-0608-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-004-0608-4

Keywords

Search

Navigation